Latest Headlines

Online Exclusive

Trump Administration to Support Work Requirements for Medicaid Beneficiaries

The Trump Administration announced it will approve proposals from states to require work or community engagement for those who want to receive Medicaid. Community...

FDA Approves First-Ever Treatment for Rare Blood Cancer

The U.S. Food and Drug Administration (FDA) expanded the approval of vemurafenib, a kinase inhibitor, to include the treatment of adult patients with BRAF-V600-mutated...

Cover Story

Predatory Publishing: The Dark Side of the Open-Access Movement

In October 2016, we dived deep into the open-access (OA) movement – a publishing model in which a scientific article is made freely available – examining the benefits and the drawbacks of this approach to research (“Public Access: The Pros and Cons of Open-Access Publishing”). This month, we take a closer look at another, darker side of scientific publishing: predatory publishing. This segment of the OA publishing movement is characterized by publishers that “unprofessionally exploit” the gold OA model (in which the final version of a manuscript is made freely available on publication), primarily for profit, according to Jeffrey Beall, MSLS, one of the most vigilant watchdogs of predatory publishing, and operator of the website Scholarly Open Access. Sometimes called “vanity presses,” these entities publish practically any materials that come their way, as long as authors are willing to pay a submission and publication fee. Critics – and they are legion...

Clinical News

Latest Videos

Mrinal Patnaik, MBBS: When Life Gives You Venoms …

In more from his pASHions interview, Mrinal Patnaik, MBBS, discusses the surprising connections between hematology and herpetology, and shares practical tips if you find...

Pulling Back the Curtain: Donna DiMichele, MD

In more from her Pulling Back the Curtain interview, Donna DiMichele, MD, tells us about her childhood in Montreal, Canada, and reflects on how...

Pulling Back the Curtain: Brian G. M. Durie, MD

In more from our interview with Dr. Durie, hear more about how interactions with his father’s doctor piqued Dr. Durie’s interest in medicine, and...

pASHions: B.Y.O.B. (Build Your Own Boat) With Joseph H. Antin, MD

In more from our interview with Dr. Antin, he offers two simple rules for starting a new hobby with your spouse, and discusses the...

On Location

Emicizumab Significantly Decreases Bleeding Rate, Compared With No Treatment in Patients With Hemophilia A

In the phase III HAVEN-1 study, preventive treatment with emicizumab significantly reduced bleeding rates, compared...

RNA Interference Therapy Fitusiran Improves Thrombin Generation in Patients With Hemophilia

The investigational RNA interference therapy fitusiran lowered levels of antithrombin in patients with hemophilia A...

Is Anticoagulant Therapy to Prevent Recurrent VTE Worth the Bleeding Risk in Older Patients With Cancer?

Though anticoagulants are common frontline treatment for patients with venous thromboembolism (VTE), patients with cancer...

Phase II Results Show Activity of Polatuzumab Vedotin Combination in DLBCL

The CD79b-targeting antibody drug conjugate polatuzumab vedotin, in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone...

Evaluating HCT Outcomes in Patients With Beta-Thalassemia

Hematopoietic cell transplantation (HCT) is associated with a disease-free survival rate of 90 percent at...

Fourth Drug’s the Charm? Comparing Combination Therapies in the Myeloma XI Trial

Triplet combinations of anti-myeloma induction therapies lead to deeper, longer remissions than doublet combinations. Results...
Advertisement

Sign Up for our enewsletter!

Subscribe to our newsletter to receive the latest news, updates and online exclusive content.

5,476FollowersFollow
4,815SubscribersSubscribe

Preexisting Cardiovascular Conditions Nearly Double Heart Failure Risk Among Non-Hodgkin Lymphoma Survivors

Patients with non-Hodgkin lymphoma (NHL) that was treated with anthracycline-based chemotherapy have an increased risk of heart failure (HF), and the chances are even...

High Rates of Depression Resulting in Higher Health-Care Costs in Patients With Sickle Cell...

Depression is approximately five times more prevalent in patients with sickle cell disease (SCD) than in the general population, and it is significantly associated...

First CAR T-Cell Therapy for B-Cell Lymphoma Receives FDA Approval

The U.S. Food and Drug Administration (FDA) approved the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (or KTE-C19) for the treatment of adult...

Remembering Harold Roberts and Tessa Holyoake, CRISPR Researchers Awarded Albany Medical Center Prize, and...

Remembering Harold R. Roberts, MD Harold R. Roberts, MD, a leader in the field of thrombosis and hemostasis and two-time American Society of Hematology (ASH)...

ASH Announces New Executive Committee Members, ASH Members Visit Congress, and more

The Results Are In … ASH Announces 2018 Executive Committee Members ASH announced the election of four new members to its Executive Committee, the governing...